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BACKGROUND. Clinical trials of monoclonal antibodies in combination with che-
motherapy have reported previously unattained response rates in patients with
B-cell chronic lymphocytic leukemia (B-CLL); however, the analysis of ZAP-70
protein and/or CD38 may explain better the discordant outcomes independent of
treatment.
METHODS. The authors conducted a Phase II study, in which rituximab was added
to fludarabine for patients with symptomatic, untreated CLL, to evaluate clinical
outcomes. Sixty patients with B-CLL received 6 monthly courses of fludarabine (25
mg/m2 for 5 days) followed by 4 weekly doses of rituximab (375 mg/m2).
RESULTS. On the basis of National Cancer Institute criteria, 47 of 60 patients (78%)
achieved a complete remission, 9 of 60 patients (15%) achieved a partial remission,
and 4 of 60 patients (7%) had no response or progressive disease. It is noteworthy
that the patients experienced a long progression-free survival (PFS) from treatment
(68% at 3 yrs). A significantly shorter PFS was observed in ZAP-70-positive patients
(25% vs. 100% at 3 yrs; P  0.00005), in CD38-positive patients (18% vs. 91% at 3
yrs; P  0.0002), and in patients who had more minimal residual disease (36% vs.
77% at 2.5 yrs; P  0.001).
CONCLUSIONS. With the addition of rituximab to fludarabine, improved clinical
outcomes were obtained, and the stratification of patients by using ZAP-70 and
CD38 may help clinicians offer more aggressive and/or experimental approaches
to the treatment of patients with high-risk B-CLL subtypes. Cancer 2005;104:
2743–52. © 2005 American Cancer Society.
KEYWORDS: B-cell chronic lymphocytic leukemia, treatment, fludarabine, rituximab,
ZAP-70, CD38, minimal residual disease, response, outcome.
Chronic lymphocytic leukemia (CLL) is the most common leukemiain the Western world and is characterized by the relentless accu-
mulation of functionally abnormal B cells. Despite the  10-year life
expectancy in early stages, patients who have progressive or ad-
vanced-stage CLL die rapidly, with a median survival between 18
months and 3 years.1,2 Promising results were observed when fludara-
bine was introduced for patients who were treated with alkylator
agents and for patients who had symptomatic, untreated CLL.3,4
Although longer progression-free survival (PFS) was reported for the
fludarabine arm in three randomized studies,5–7 significant improved
survival with fludarabine therapy has not been observed to date in
patients with CLL. There is an interest in developing new combina-
tion therapies for CLL with agents that can be added to fludarabine to
increase the complete remission (CR) rate, because disease recur-
rence in patients with CLL most probably is the result of residual
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tumor cells. In fact, studies using minimal residual
disease (MRD) assays may be better for confirming a
true CR, which is the major therapeutic objective in
patients with CLL, to improve PFS and, finally, overall
survival (OS). Combinations that include agents with
lower toxicity than fludarabine represent a potential
advantage over combination strategies with cytotoxic
chemotherapy. Rituximab is a chimeric monoclonal
antibody directed against the cell-surface antigen
CD20, which is active in low-grade and diffuse, large-
cell, non-Hodgkin lymphoma (NHL).8 –10 Rituximab
also has single-agent activity in CLL, mainly at esca-
lating doses.11,12 Moreover, experimental data indicate
a potential superadditive effect of combining ritux-
imab with fludarabine because of diminished bcl-2
expression.13 In addition, rituximab can enhance the
sensitivity of tumor cells to chemotherapy-induced
apoptosis, and one preclinical study demonstrated
synergy between rituximab and fludarabine.14 Two
Phase II studies combining rituximab with fludarabine
demonstrated a much higher CR rate than was ob-
served previously with any other therapeutic approach
that had been used previously in patients with
CLL.15,16 However, the analysis of different biologic
parameters may explain better the discordant out-
comes independent of the treatment observed in
those studies. In fact, the evolution of risk-stratifica-
tion models has advanced from clinical staging to
include relevant immunologic and genetic features.
Recent data from the literature indicate that unmu-
tated VH genes, CD38, ZAP-70 protein tyrosine kinase
overexpression, and MRD may predict a lower re-
sponse, a shorter PFS, and a shorter OS.17–26 On the
basis of the rationale of the synergistic effects of flu-
darabine and rituximab, we conducted a Phase II trial
investigating the safety and efficacy of a sequential
application schedule in patients with previously un-
treated CLL. Moreover, we evaluated the differential
clinical impact of relevant biologic features, such as
ZAP-70, CD38, and MRD, as determined by flow cy-
tometry, on the outcomes of these homogeneously
treated patients.
MATERIALS AND METHODS
This prospective Phase II study was conducted be-
tween December 1997 and March 2004 in accordance
with the Declaration of Helsinki. All eligible patients
provided written informed consent. Patients were re-
quired to have histologically and immunophenotypi-
cally documented CLL, as defined by the modified
National Cancer Institute (NCI) 1996 guidelines.27 All
patients either required therapy for Rai Stage I–II dis-
ease or had Rai Stage III–IV disease, as defined by the
NCI 1996 guidelines. Eligible patients must have re-
ceived no prior therapy for CLL. An Eastern Coopera-
tive Oncology Group (ECOG) performance status of
0 –3 was required. Patients were excluded if they had a
positive Coombs test, active opportunistic infections,
any other severe infection that was not controlled by
medical therapy, or major organ dysfunction.
Treatment Plan
Patients received fludarabine (25 mg/m2) intrave-
nously daily on days 1–5 in 28-day intervals for a total
of 6 cycles. Then, after a median of at least 40 days
(range, 30 –155 days), patients underwent restaging
(physical examination, complete blood count [CBC]
with manual differential, bone marrow aspirate and
biopsy) to determine their response to induction ther-
apy. Patients who had stable disease or better, as
defined by the NCI criteria, were treated with 4 weekly
doses of rituximab (375 mg/m2) with an administra-
tion procedure identical to that described for the NHL
trials (Fig. 1).28 Clinical restaging was repeated after
rituximab therapy; patients were observed for approx-
imately 1 month and then completely restaged (phys-
ical examination, CBC with manual differential, bone
marrow aspirate and biopsy) to determine overall re-
sponse according to the NCI 1996 criteria.27
Assessment and Management of Toxicity
Hematologic toxicity was graded according to the
modified NCI criteria for CLL,27 whereas nonhemato-
logic toxicity was graded according to the NCI Com-
FIGURE 1. Treatment scheme of fludarabine combined with rituximab.
Patients received 6 monthly courses of fludarabine and 4 weekly doses of
rituximab starting an average of 40 days after they completed fludarabine
therapy. CR: complete remission; PR: partial remission.
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mon Toxicity Criteria. Infusion toxicity was assessed
according to the criteria previously described by Byrd
et al.16 Patients who experienced Grade 3 or 4 neutro-
penia/thrombocytopenia or Grade 2 anemia were
supported with growth factors (granulocyte-colony
stimulating factor and erythropoietin ) and remained
without treatment until these hematologic parameters
recovered within 50% of baseline values. Thereafter,
these patients received the same original dose. There
were no dose reductions for rituximab therapy be-
cause of hematologic toxicity. Acute infusion toxicity
after rituximab administration that was reversible did
not require subsequent dose reduction of this agent.
At the onset of fever, chills, rigors, or other infusional
reactions, patients had their infusion discontinued
and received an additional dose of dipheninhydra-
mine (50 mg) and acetaminophen (650 mg). After the
resolution of symptoms, the rituximab infusion was
restarted at a rate of 50 mg per hour and then was
escalated, as tolerated, to 200 mg per hour. Patients
who developed an infection were observed without
further CLL treatment until the infection had resolved,
but no dose reductions were implemented. Nonhema-
tologic toxicities, including nausea, emesis, fatigue,
diarrhea, and drug-related fever and chills, required
no dose reductions.
Patient Monitoring and Response Evaluation
Baseline assessment included disease history, current
disease stage, B symptoms, and measurement of le-
sions by physical examination and radiography (chest
X-ray, computed tomography scan, ultrasound). The
histologic examination of representative material
(bone marrow biopsy and aspirate, immunopheno-
type of peripheral blood) had to be performed at least
6 months before enrollment. Laboratory testing in-
volved CBC with differential, flow-cytometric pheno-
typing of lymphocytes of the peripheral blood, and
clinical chemistry, including immunoglobulins (Ig),
2-microglobulin, and Coombs test.
Patients were assessed for response 4 – 6 weeks
after the last rituximab infusion with a detailed clinical
evaluation (physical examination with measurement
of lymph nodes, liver, and spleen; CBC with differen-
tial; bone marrow biopsy and aspirate). Criteria for
response used the revised 1996 NCI Working Group
guidelines.27 A CR or partial remission (PR) had to be
maintained for  8 weeks. PFS was defined as the time
from the end of treatment in the subgroup of patients
who achieved a CR or PR until the last follow-up, the
time at which progression occurred or further therapy
for symptomatic CLL was required, or death that oc-
curred from any cause. Survival was measured from
the date of initiation of treatment either until the last
time the patient was seen alive or until death.
Sample Size Determination
A single-stage design according to the method of
Fleming 29 was selected based on the following as-
sumptions: 1) The treatment in this study would not
be considered sufficiently effective if the global re-
sponse rate (CR plus PR) was  60%. 2) The combi-
nation treatment with fludarabine and rituximab
would be regarded as very promising for a Phase III
comparative trial if the true response rate exceeded
80%. 3) The probability of erroneously declaring the
drug active for further investigation, despite a true
response rate  60% (type I error), was set at 5%. 4)
The probability of erroneously rejecting the therapy as
not sufficiently active ( 60%) if there was a promising
true response rate ( 90%) was 10% (type II error;
power  90%).
With regard to feasibility and tolerability, a failure
rate of up to 10% was considered acceptable, and the
sample size for the evaluation of treatment overall
efficacy was set to 60 patients. Moreover, because a
major objective of the study was to detect the role of
classification of patients into groups of different sizes
dichotomized according to specific biologic predic-
tors, such as ZAP-70, CD38, and MRD, specific post-
hoc power calculations were performed for PFS on any
grouping, based on the number of events and on the
hazard ratio between groups at the end of the ob-
served time, according to the method described by
Norman and Streiner.30
Cellular Immunophenotypic Analysis
The following antibody conjugates were used: anti-
CD23-phycoerythrin (PE), anti-CD5-fluorescein iso-
thiocyanate (FITC), anti-CD38-PE, anti-CD19-allophy-
cocyanin (APC), anti-CD45-FITC, anti-CD14-PE, anti-
CD95-PE, and anti-CD10-FITC (Becton Dickinson
Immunocytometry Systems, San Jose, CA). Peripheral
blood mononuclear cells were analyzed for surface
expression of CD19/CD5/CD38 and CD19/CD5/CD23
by triple-color immunofluorescence, as described pre-
viously.20
ZAP-70 protein determination also was performed
by flow cytometry, as described elsewhere.23 Flow-
cytometric analyses were performed on a FACS Cali-
bur flow cytometer (Becton Dickinson Immunocy-
tometry Systems), and CellQuest software was used to
acquire and analyze data. The threshold of positivity
both for CD38 and for ZAP-70 was set at  20% of
CD19-positive/CD5-positive B-cells.
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MRD Flow-Cytometric Study
Between 50,000 and 300,000 total cells were analyzed
in each test that was performed in bone marrow ap-
proximately 1–2 months after the completion of com-
bined therapy. The antibodies used were anti-CD5-
APC, anti-CD20-PE, anti-CD19-peridin-chlorophyll
protein, anti-CD38-PE, anti-CD20-FITC (Becton Dick-
inson Immunocytometry Systems) and anti-CD79b
FITC (Serotec, Oxford, United Kingdom). The 2 com-
binations CD19/CD5/CD20/CD79b and CD19/CD5/
CD38/CD20 allowed to discriminate B-CLL cells from
normal B cells in all samples, as described previous-
ly.26 The threshold for positivity was set at  5% CD19-
positive/CD5-positive/CD79b-negative CLL cells.
Interphase Fluorescence in Situ Hybridization
Separate hybridizations were carried out for loci on
chromosomes 11, 12, 13, and 17. For chromosomes 11
(q23), 13, and 17, commercial probes (ATM-2, Rb-1,
and p53, respectively) were used (Vysis Inc., London,
UK). An  satellite DNA probe, CEP12, which was
labeled directly with SpectrumGreen, was used to de-
tect aneuploidy of chromosome 12. LSIp53 labeled
with SpectrumOrange (Vysis Inc.) was used to evaluate
chromosome deletion at 17p13.1. The procedure used
was described previously.31
IgVH Mutation Analysis
Total RNA was extracted and reverse transcribed, as
described previously.32 The resulting cyclic DNAs,
which were checked for first-strand synthesis, were
amplified using a mixture of sense primers and an-
nealing either to the VH1–VH6 leader sequences or to
the 5 end of VH1–VH6 FR1, as reported elsewhere.
33,34
These primers were used in conjunction with a mix-
ture of antisense primers complementary to the germ-
line JH regions. The purified, amplified products,
which were inserted into the PCR2.1-TOPO vector (In-
vitrogen, Milan, Italy), were expanded in TOP10 One
Shot™ competent cells (Invitrogen) and cloned. Plas-
mid DNAs were isolated from overnight cultures of
randomly selected colonies and were sequenced by
using an automatic DNA sequencer (Beckman
CEQ2000XL; Beckman Coulter, Hialeah, FL). Compar-
isons between the obtained sequences and the se-
quences of the various germline IgVH genes were per-
formed with the IgBLAST directory (http://www.
ncbi.nlm.nih.gov/igblast) using Mac Vector 7.1 se-
quence-analysis software (Accelerys; Symantec, San
Diego, CA). Only when the same VHDJH rearrange-
ment was identified in at least 5–10 clones was a given
IgVH sequence analyzed further. Alignment of the IgVH
sequences available for each patient often revealed,
along with mutations shared by all the transcripts
analyzed, several unique or partially shared muta-
tions. For this reason, all mutational analyses were
carried out in each IgVH transcript separately, and the
percentage mutation assigned to a given B-CLL was
the mean value of the percentage of mutation found in
each transcript. VH gene sequences that deviated  2%
from the corresponding germline gene were defined
as mutated.
Statistical Analysis
For the efficacy analysis, patients had to have received
at least one cycle of therapy. All patients who had
received at least one application of study therapy also
were evaluable for toxicity. Rate comparisons between
patients subgroups were performed by using the two-
tailed Fisher exact test. Event-related data (survival
and PFS) were estimated by using the Kaplan–Meier
product-limit method. Prognostic subgroups were
compared by using the log-rank test. Statistical anal-
yses and Kaplan–Meier curves were performed using
STATA 8.0 and Statistica 6.0 for Windows.
RESULTS
Patient Characteristics
In total, 60 patients were enrolled in the current study
between December 1997 and March 2004. The pre-
treatment features of these patients are summarized
in Table 1. The median age was 59 years (range, 37–74
yrs). All patients met the guideline criteria for having
TABLE 1
Patient Characteristics (n  60)
Characteristic No. of patients (%)
Median age in yrs (range) 59 (37–74)









B symptoms 17 (28)
Time since first diagnosis
 1 yr 17 (29)
2–5 yrs 29 (48)
 5 yrs 14 (23)




ECOG: Eastern Cooperative Oncology Group.
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CLL.27 According to Rai staging criteria,1 5 patients
(8%) had low-risk (Stage 0) CLL, 52 patients (87%) had
intermediate-risk (Stage I or II) CLL, and 3 patients
(5%) had high-risk (Stage III or IV) CLL. In this mod-
ified classification scheme, patients with intermedi-
ate-risk CLL have lymphadenopathy or hepatospleno-
megaly without significant cytopenias, whereas
patients with high-risk CLL have anemia or thrombo-
cytopenia. Much greater than one-half of patients
(62%) had a good ECOG performance status of 0. The
time from diagnosis ranged from 1 year to 10 years.
Only 28% of patients exhibited B symptoms. Finally,
the histologic patterns of bone marrow infiltration
were mainly diffuse (58%) or mixed (35%).
Toxicity
All patients were evaluable for toxicity. The three most
frequent side effects were infusion-related toxicity,
myelosuppression, and infections. Five of 58 patients
who were treated with rituximab experienced a mild,
infusion-related symptom complex, which consisted
of fever, chills, and rigors, during the first infusion.
There were 13 opportunistic infections, including 3
dermatomal herpes zoster infections, 7 localized her-
pes simplex infections, 2 episodes of Grade 3 pulmo-
nary toxicity (isolated interstitial pneumonitis and
Candida pneumonia), and 1 incident of fulminant B
hepatitis. The reported infectious toxicity was con-
fined to the first 12 months of therapy, but no signif-
icant opportunistic infections were noted after this
period in patients observed in CR or PR without fur-
ther treatment. Hematologic toxicity (Table 2) in-
cluded neutropenia (Grade 1 and/or 2 in 12 patients,
Grade 3 and/or 4 in 29 patients), thrombocytopenia
(Grade 1 and/or 2 in 4 patients, Grade 3 and/or 4 in 3
patients), and anemia (Grade 2 in 3 patients). In par-
ticular, Grade 3 and 4 neutropenia was observed in 25
of 60 patients (41%) during fludarabine infusions and
in 9 of 58 patients (16%) during rituximab treatment.
Thrombocytopenia and anemia were noted only dur-
ing fludarabine cycles.
Response to Treatment and Treatment Outcome
All patients enrolled on this study were evaluable for
response. Response evaluation occurred at least 1
month after the completion of fludarabine therapy
(induction response) and then again 2 months after
the completion of all therapy (fludarabine plus ritux-
imab). The response rate included an induction CR
rate of 70% and an overall response rate of 92%. Of 13
patients who had a PR after induction who received
rituximab, 4 patients (31%) had a conversion to a CR.
The comprehensive response rate included a 78% CR
rate and an overall response rate of 93% (95% confi-
dence interval [95% CI], 84 –98%) (Table 3). Only 1
patient with stable disease after fludarabine therapy
had a conversion to a CR after receiving rituximab
therapy. Outcome data relative to PFS and OS are
shown in Figures 2 and 3. After a median of 27 months
of follow-up, 9 of 56 patients (16%) experienced a
recurrence. The estimated 3-year PFS rate was 68%
(95% CI, 46 – 83%) (Fig. 2). Among the 60 patients
TABLE 2
Hematologic Toxicity During the Treatment Period
Toxicity
No. of patients (%)
NCI Grade 1-2 NCI Grade 3-4
Anemia 3 (5) 0 (0)
Neutropenia 12 (20) 29 (48)
Thrombocytopenia 4 (7) 3 (5)
NCI: National Cancer Institute.
TABLE 3
Comprehensive Response Rate According to Baseline Patient Features
(n  60)
Variable
No. of patients (%)
OR CR PR SD PD
Total group (n  60) 56(93) 47(78) 9(15) 1(2) 3(5)
Low stage (n  5) 5(100) 5(100) — — —
Intermediate stage (n  52) 49(94) 41(79) 8(15) — 3(6)
High stage (n  3) 2(66) 1(33) 1(33) 1(33)
No B-symptoms (n  43) 43(100) 42(98) 1(2) — —
B-symptoms (n  17) 13(76) 5(29) 8(47) 1(8) 3(16)
OR: overall response; CR: complete response; PR: partial response; SD: stable disease; PD: progressive
disease.
FIGURE 2. Kaplan–Meier analysis of progression-free survival showed the
proportion of 56 patients who had a response to treatment and remained in
complete or partial remission. The estimated 3-year progression-free survival
rate was 68%, and 9 of 56 patients (16%) experienced a recurrence.
Fludarabine plus Rituximab in B-CLL/Del Poeta et al. 2747
enrolled in this study, 6 patients died. One patient
died in CR of fulminant B hepatitis, two other patients
died of progressive CLL that was resistant to fludara-
bine induction, and the other three patients died of
progressive CLL after they received the prescribed
protocol therapy.
Clinical and Biologic Features Predicting Response and
Outcome
We examined whether age, gender, or 2-microglobu-
lin level predicted a CR during fludarabine plus ritux-
imab therapy. A higher CR rate was not correlated with
gender, age, or 2-microglobulin level (P  0.30 for all
variables). Conversely, there was a trend toward a
correlation between the CR rate and the modified Rai
stage, because all patients with low Rai stage CLL (n
 5 patients) achieved a CR (P  0.05).
Twenty-eight patients (46.7%) had ZAP-70 expres-
sion levels  higher than 20% (range, 4 – 65%), and 19
of 60 patients (31.7%) presented CD38 levels  20%
(range, 1– 66%). Tests for MRD, which were performed
on bone marrow by flow cytometry after the protocol
therapy, were positive ( 5% CD19-positive/CD5-pos-
itive/CD79b-negative CLL cells) in 15 of 60 patients
(25%). Forty patients were analyzed by interphase flu-
orescence in situ hybridization (FISH): Twenty pa-
tients (50%) had a normal karyotype, 14 patients (35%)
had a 13q abnormality, 4 patients (10%) had trisomy
12, 1 patient (2.5%) had 11q, and 1 patient (2.5%)
had 17p. No significant correlation was found be-
tween these cytogenetic abnormalities and ZAP-70 or
CD38 expression levels. Thirty-two patients were an-
alyzed for IgVH mutations: Fifteen of 16 patients with
IgVH mutations  2% presented with ZAP-70 protein
levels  20% (P  0.0006). Moreover, the strict corre-
lation between CD38 and IgVH mutational status was
confirmed (15 of 16 patients with IgVH mutations
 2% showed CD38 levels  20%, P  0.0006).
With regard to clinical outcomes, all 32 patients
who had ZAP-70 expression levels  20% achieved a
CR or a PR (P  0.001), and a significant higher overall
response rate was found among CD38-negative pa-
tients (98% vs. 84%; P  0.027) (Table 4). No signifi-
cant correlation was found between cytogenetic ab-
normalities and overall response. Moreover, 42 of 47
patients (93%) who achieved a CR based on NCI cri-
teria were negative for MRD according to flow cytom-
etry ( 5% CD19-positive/CD5-positiveCD79b-nega-
tive CLL cells in bone marrow; P  0.0001). Finally, all
but 1 patient (15 of 16 patients) who presented with
IgVH mutations  2% achieved a CR (P  0.01).
A significantly shorter PFS was observed in ZAP-
70-positive patients (25% [95% CI, 5–54%] vs. 100% at
3 yrs; P  0.00005) (Fig. 4A), in CD38-positive patients
(18% [95% CI, 1–52%] vs. 91% [95% CI, 66 –98%] at 3
yrs; P  0.0002) (Fig. 4B), and in patients with higher
MRD after treatment (36% [95% CI, 6 – 69%] vs. 77%
[95% CI, 48 –91%] at 2.5 yrs; P  0.001) (Fig. 4C).
Moreover, unmutated patients also showed a signifi-
cantly shorter PFS rate (0% vs. 50% at 2 yrs; P  0.01).
Similarly, OS was significantly shorter in ZAP-70-
positive patients (68% [95% CI, 40 – 85%] vs. 100% at 3
yrs; P  0.006) and in MRD-positive patients (72%
[95% CI, 42– 88%] vs. 89% [95% CI, 62–97%] at 3 yrs; P
 0.018) and showed a significant trend in CD38-
positive patients (70% [95% CI, 36 – 89%] vs. 92% [95%
CI, 68 –98%] at 3 yrs; P  0.059). Finally, cytogenetic
abnormalities showed no significant prognostic im-
pact with regard either PFS or OS.
With regard to PFS, post-hoc power was not cal-
culable for ZAP-70 group comparisons, because we
FIGURE 3. Kaplan–Meier analysis of overall survival included all 60 patients
with chronic lymphocytic leukemia who were treated with a sequential flu-
darabine and rituximab regimen. Six patients died either from progressive
disease or from opportunistic infections.
TABLE 4
Comprehensive Response Rate According to ZAP-70
and CD38 Expression
Expression status
No. of patients (%)
OR CR PR SD PD
ZAP-70
Positive (n  28)a 24(86) 16(57) 8(29) 1(4) 3(10)
Negative (n  32) 32(100%) 31(97%) 1(3) — —
CD38
Positive (n  19)b 16(84) 11(58) 5(26) — 3(16)
Negative (n  41) 40(98) 36(88) 4(10) 1(2) —
OR: overall response; CR: complete response; PR: partial response; SD: stable disease; PD: progressive
disease.
a P  0.001 (CR vs. PR vs. SD vs. PD; two-tailed Fisher exact test).
b P  0.027 (CR vs. PR vs. SD vs. PD; two-tailed Fisher exact test).
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found that no event (progression) took place in the
group of ZAP-70-positive patients. For CD38, post-hoc
power was 0.79; whereas for MRD, post-hoc power
was 0.22.
DISCUSSION
In this Phase II study, we demonstrated clearly that
combined immunochemotherapy with six cycles of
fludarabine followed by four cycles of rituximab was
safe and very effective in patients with previously un-
treated B-CLL. The overall response rate was 93%,
with a CR rate of 78% and a PR rate of 15%. This very
high CR rate probably was achieved because almost all
patients (57 of 60 patients) had CLL with low or inter-
mediate Rai stage. In any event, all treated patients
had progressive disease and presented with at least 1
of the following parameters: a lymphocyte doubling
time  1 year, disease progression to a more advanced
Rai modified stage, or the development of systemic
symptoms. Schulz et al.15 also demonstrated that
there were more CRs among patients who had Binet B
CLL (43%) compared with patients who had Binet C
CLL (11%) in a similar Phase II trial that was based on
a regimen combining rituximab and fludarabine. A CR
rate of 28% (PR rate, 49%) was obtained in patients
with B-CLL who had both Rai intermediate-risk CLL
(58%) and Rai high-risk CLL (42%) and were treated
with a sequential scheme based on fludarabine plus
rituximab.16 Our sequential regimen was very effective
in the patients with intermediate Rai stage disease, as
shown above (see Results), and the treatment of this
progressive subset before the appearance of anemia or
thrombocytopenia allowed us to obtain very good re-
sults in terms of both response and duration of re-
sponse. The long-term benefit of this therapy as it
relates to PFS and OS is not yet clear, and even if it is
superior to fludarabine alone remains undetermined.
It is noteworthy that our patients with B-CLL who
were treated sequentially with fludarabine and ritux-
imab experienced a long PFS after treatment (68%
were alive at 3 yrs). Recently, Cancer and Leukemia
Group B (CALGB) tested this combined regimen
against monotherapy with fludarabine in a retrospec-
tive, Phase III clinical trial and demonstrated that,
with fludarabine plus rituximab, significantly longer
PFS (P  0.0001) and OS (P  0.0006) were achieved.35
The fludarabine plus rituximab treatment regi-
men is feasible and can be administered safely on an
outpatient basis. Rituximab causes important and
prolonged depletion of B lymphocytes. Conversely,
fludarabine leads to profound depletion of T cells.36,37
The risk of opportunistic infections may increase
greatly with the combination of fludarabine and ritux-
imab. In the current study, toxicity was moderate, and
there was a slightly increased risk of severe infections.
The majority of these opportunistic infections were
viral and often localized. There were only 3 patients
with Grade 3 or 4 infections, 1 of which was fatal (B
hepatitis). Grade 3 and/or 4 hematologic toxicity was
observed almost exclusively for neutropenia (48%),
compared with thrombocytopenia (5%). These per-
centages of serious neutropenia were inferior to those
published by Byrd et al.,16 who reported that 76% of
their patients had Grade 3 or 4 neutropenia, probably
because of the greater numbers of rituximab infu-
sions. Nonetheless, this excess neutropenia did not
predispose to an excess number of neutropenic fever
episodes or life-threatening infections either in the
study by Byrd et al.16 or in our current study.
Moreover, there were no episodes of autoimmune
hemolytic anemia, probably because the transient B-
FIGURE 4. Progression-free survival curves were based on ZAP-70, CD38,
and minimal residual disease (MMR) expression. Progression-free survival was
significantly shorter in patients with ZAP-70 levels  20% (ZAP-70 positive
[]) (A), CD38 levels  20% (CD38) (B), and (C) MRD  5% (MMR).
Fludarabine plus Rituximab in B-CLL/Del Poeta et al. 2749
cell depletion caused by rituximab may avoid the de-
velopment of fludarabine-associated hemolytic ane-
mia. This hypothesis is corroborated by the findings of
some authors who observed effective treatment of au-
toimmune hemolytic anemia with rituximab.38 One
concern about the use of rituximab in patients with
CLL is infusion-related toxicity. This problem arises
from studies demonstrating that rituximab can cause
severe infusion-related toxicity in a minority of pa-
tients and that a high number of circulating B-CLL
cells may predispose patients to this toxicity.39,40 In
our study, only 5 patients presented with mild infu-
sion-related symptom complex, consisting of fever,
chills, and rigors, during the first infusion. Probably,
prior treatment with fludarabine greatly diminished
the infusion toxicity observed with subsequent ritux-
imab treatment, mainly because of lower leukocyte
counts.
The low CR rate obtained with previous therapies
in patients with CLL relates to several different mech-
anisms of disrupted apoptosis.41 Both fludarabine and
rituximab enhance different proapoptotic mecha-
nisms, based both on bcl-2 down-modulation and
caspases activation, so that this combined regimen
allowed us to achieve better responses compared with
single-agent fludarabine or rituximab.42
Various clinical features, including age, Rai stage,
and serum 2-microglobulin levels, have been associ-
ated with lower response rates and poor long-term
treatment outcomes after alkylator-based and purine
analog-based therapy for patients with CLL.43,44 Sev-
eral standard prognostic factors, including age, gen-
der, Rai stage, and 2-microglobulin levels, did not
reach a level of significance for predicting treatment
outcomes either in the current study or in the ran-
domized Phase II study by CALGB 9712.16
Recent studies examining molecular aberrations
(i.e., p53 mutations), unfavorable cytogenetics, CD38
expression, somatic VH gene mutational status, and
ZAP-70 expression, have demonstrated that all of
these factors are important determinants for treat-
ment outcomes in patients with CLL.45 Therefore, the
analysis of unmutated VH genes, CD38 expression,
and/or ZAP-70 protein expression may be better for
explaining the discordant outcomes independent of
treatment that were observed in these studies. It is
noteworthy that, in the current study, ZAP-70 and
CD38 overexpression identified a subset of patients
with a poor prognosis in terms of overall response,
PFS, and OS. Thus, these two markers prospectively
may identify subsets of patients who have a low like-
lihood of responding to combination therapy with
fludarabine and rituximab. In our experience, FISH
analysis did not allow us to obtain significant different
risk subsets with regard to response and outcome,
perhaps because of the small number of patients an-
alyzed. Conversely, MRD assays by flow cytometry
allowed us to identify patients who were at signifi-
cantly greater risk of recurrence. This is important,
because, based on NCI criteria, patients in CR who are
MRD-positive (5 of 47 patients in the current study)
may be eligible for some consolidation therapy to
avoid disease recurrence. These observations may en-
courage the use of cyclophosphamide combined with
fludarabine and rituximab in these patient subsets
with “poor-risk” B-CLL. In fact, investigators at The
University of Texas M. D. Anderson Cancer Center
used this triple combination and reported a CR rate of
66% in patients with previously untreated CLL.46 The
ultimate objective in CLL therapy is not only to
achieve high CR rates but also mainly to avoid recur-
rence, thus prolonging remissions and, finally, sur-
vival. The introduction for stratification purposes of
some biologic markers, such as ZAP-70 and CD38, into
clinical practice may allow us prospectively to isolate
patients who respond poorly to fludarabine plus rit-
uximab and who may be potential candidates for
more aggressive and/or experimental approaches.47
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